Trial Profile
Phase II Multi-Center Study of PARP Inhibitor Rucaparib in Combination With Anti-PD-1 Antibody Nivolumab in Patients With Advanced or Metastatic Biliary Tract Cancer Following Platinum Therapy
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 01 Sep 2023
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary) ; Rucaparib (Primary)
- Indications Adenocarcinoma; Biliary cancer; Gallbladder cancer
- Focus Therapeutic Use
- 30 Aug 2023 Planned End Date changed from 1 Apr 2024 to 1 Feb 2025.
- 06 Jun 2023 Primary endpoint has not been met, (Proportion of patients alive and without radiological or clinical progression at 4 months), as per Results presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 06 Jun 2023 Results presented at the 59th Annual Meeting of the American Society of Clinical Oncology